CN105560838A - 一种用于辅助治疗糖尿病的雨生红球藻虾青素及其制造方法 - Google Patents
一种用于辅助治疗糖尿病的雨生红球藻虾青素及其制造方法 Download PDFInfo
- Publication number
- CN105560838A CN105560838A CN201610066177.0A CN201610066177A CN105560838A CN 105560838 A CN105560838 A CN 105560838A CN 201610066177 A CN201610066177 A CN 201610066177A CN 105560838 A CN105560838 A CN 105560838A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- preparation
- polysaccharide
- diabetes
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 53
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 53
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 52
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 52
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 52
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 30
- 241000168517 Haematococcus lacustris Species 0.000 title claims abstract description 20
- 238000009098 adjuvant therapy Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract 12
- 150000004676 glycans Chemical class 0.000 claims abstract description 31
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 31
- 239000005017 polysaccharide Substances 0.000 claims abstract description 31
- 239000000843 powder Substances 0.000 claims abstract description 14
- 235000009854 Cucurbita moschata Nutrition 0.000 claims abstract description 11
- 239000000725 suspension Substances 0.000 claims abstract description 11
- 239000000230 xanthan gum Substances 0.000 claims abstract description 9
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 9
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 9
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 9
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 8
- 239000003094 microcapsule Substances 0.000 claims abstract description 7
- 239000000839 emulsion Substances 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 240000004244 Cucurbita moschata Species 0.000 claims description 9
- 235000009852 Cucurbita pepo Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 235000020354 squash Nutrition 0.000 claims description 9
- 239000003292 glue Substances 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 229920000161 Locust bean gum Polymers 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000711 locust bean gum Substances 0.000 claims description 4
- 235000010420 locust bean gum Nutrition 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 230000006378 damage Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract description 4
- 208000033679 diabetic kidney disease Diseases 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000003914 insulin secretion Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract 4
- 241001061264 Astragalus Species 0.000 abstract 2
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 2
- 235000000832 Ayote Nutrition 0.000 abstract 2
- 240000001980 Cucurbita pepo Species 0.000 abstract 2
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 abstract 2
- 235000006533 astragalus Nutrition 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 2
- 235000015136 pumpkin Nutrition 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000037831 Polygonatum sibiricum Species 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种用于辅助治疗糖尿病的雨生红球藻虾青素产品的制备方法,属于保健品、生物制药等领域,它通过将黄芪、黄精、枸杞的提取液加入南瓜多糖、黄原胶、虾青素乳化液混匀后,加入多糖胶液进行匀质、悬浮化,获得多糖悬浮液,再将多糖悬浮液瓶装、灭菌后获得产品,也可通过将黄芪、黄精、枸杞的提取液浓缩、干燥后获得的浓缩粉、将虾青素乳化并低温真空干燥获得的虾青素微囊粉和南瓜多糖压片,获得片剂产品。本发明达到的有益效果是它制备出的雨生红球藻虾青素产品含有唯一可以有效阻止糖尿病肾病损害的物质,并辅以治疗糖尿病的其他中药成分,可以从根本上改善糖尿病症状,促进胰岛素分泌,是一种辅助治疗糖尿病的新型产品。
Description
技术领域
本发明涉及一种用于辅助治疗糖尿病的雨生红球藻虾青素及其制造方法,特别是一种利用雨生红球藻虾青素、黄芪、黄精、枸杞、南瓜多糖制造可辅助治疗糖尿病的雨生红球藻虾青素产品的方法,属于保健品、生物制药等领域。
背景技术
雨生红球藻虾青素是一种类胡萝卜素,具有多种生理功效,其中之一是抑制糖尿病肾病,它是唯一可以有效阻止糖尿病肾病损害的物质。虾青素主要是通过直接保护肾小球基底膜、阻止因高血糖产生的自由基来破坏基底膜;此外,还可以对抗肾小管上皮细胞的自由基,保护葡萄糖及磷在肾小管细胞的正常转运,从而保存ATP及钠-钾ATP酶这些重要物质,确保肾脏血流不受影响,减少蛋白尿的产生。具体来说,虾青素可降低自由基含量及其诱发的脂质过氧化;减少自由基对胰岛β细胞的损伤;降低血糖浓度等。总之,雨生红球藻虾青素可显著改善糖尿病症状,促进胰岛素分泌,提高机体抗氧化能力。
黄芪是一种多年生草本植物,药用历史已有2000多年,它具有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌等作用。它可用于治疗急慢性肾炎水肿、脾肾虚,临床上作为治疗糖尿病的药物之一。
黄精又名鸡头黄精、黄鸡菜、笔管菜、爪子参、老虎姜、鸡爪参,为黄精属植物,具有补脾,润肺生津的作用。它的药用价值之一是抑制糖尿病,对肾上腺素引起的血糖过高呈显着抑制作用。
枸杞为灌木,人们日常食用和药用的枸杞子多为宁夏枸杞,它与琼珍灵芝、长白山人参,东阿阿胶并称为中药四宝。它的药理作用主要为提高人们的免疫功能,具有养肝,滋肾,润肺的功效。
糖尿病是严重危害人类健康的疾病之一,是由遗传和环境因素相互作用引起的胰岛素分泌异常伴有或不伴有胰岛素抵抗而导致以慢性血葡萄糖水平增高为特征的代谢性疾病。研究表明,糖尿病出现糖、脂和蛋白多种物质的代谢紊乱,常伴有各种氧化应激、炎症、细胞凋亡和器官受损的现象,其中,糖尿病人70%会在5年内发展为肾病损害。
糖尿病的主要症状是“三多一高”和高血糖。现有研究表明,除遗传外引起糖尿病的可能因素有以下两个方面:机体内脂质过氧化;自由基过高损伤胰岛β细胞。
传统的糖尿病治疗主要是通过药物治疗,口服降血糖药物虽然可以抑制血糖的升高,但没有从根本上解决引起糖尿病的问题,并且会使患者产生依赖性,还具有一定的毒副作用。
发明内容
本发明的目的是克服现有技术的缺陷,提供一种用于辅助治疗糖尿病的雨生红球藻虾青素及其制造方法,它包括以下步骤:
1):按2-5:2-5:1-2的比例称取黄芪、黄精、枸杞,加水,加热浸提,除渣,获得提取液;
2):将虾青素油乳化获得虾青素乳化液;
3):将南瓜多糖、黄原胶、步骤2)获取的虾青素乳化液和步骤1)获得的提取液按0.2-4:0.05-1:1-5:1-5的比例混匀,获得多糖混合液;
4):将缓冲液加入到步骤3)获得的多糖混合液中,PH调节至2-7.5;
5):将多糖胶液加入到步骤4)中调节PH后的多糖混合液中,匀质、悬浮化后,获得多糖悬浮液;
6):将步骤5)获得的多糖悬浮液瓶装、灭菌后获得产品。
步骤1)中的加水量为黄芪、黄精、枸杞总量的10-100倍,加热温度为60-100℃,浸提时间为1-8小时。
步骤1)的除渣方法为过滤或离心。
步骤3)的缓冲液为磷酸氢二钾与柠檬酸或磷酸氢二钾与酒石酸或磷酸氢二钾与苹果酸或磷酸氢二钾与乳酸或磷酸氢二钾与醋酸。
步骤5)多糖胶液为黄原胶、槐豆胶、卡拉胶中的一种、两种或三种配置而成的胶液。
本发明提供的一种用于辅助治疗糖尿病的雨生红球藻虾青素及其制造方法,也可通过以下步骤实现:
1):按2-5:2-5:1-2的比例称取黄芪、黄精、枸杞,加水,加热浸提,除渣,获得提取液;
2):将步骤1)获得的提取液浓缩、干燥,获得浓缩粉;
3):将虾青素油乳化获得虾青素乳化液,将虾青素乳化液经低温真空干燥获得虾青素微囊粉;
4):将步骤2)获得的浓缩粉、步骤3)获得的虾青素微囊粉、南瓜多糖作为主要原料,压片,获得片剂产品。
步骤1)中的加水量为黄芪、黄精、枸杞总量的10-100倍,加热温度为60-100℃,浸提时间为1-8小时。
步骤1)的除渣方法为过滤或离心。
与现有技术相比,本发明达到的有益效果是它制备出的雨生红球藻虾青素产品含有唯一可以有效阻止糖尿病肾病损害的物质—雨生红球藻虾青素,并辅以治疗糖尿病的其他中药成分,可以从根本上改善糖尿病症状,促进胰岛素分泌,提高机体抗氧化能力,是一种辅助治疗糖尿病的新型产品,给糖尿病患者带来新的福音。
附图说明
图1是本发明的工艺流程图。
具体实施方式
下面结合实施例对本发明做进一步阐述,而不是要以此对本发明进行限制。
实施例1:
1):称取黄芪20g、黄精20g、枸杞10g,加入500g水,加热60℃,浸提时间为1小时后,过滤除渣,获得提取液;
2):将虾青素油乳化获得虾青素乳化液200g;
3):将南瓜多糖50g、黄原胶25g、步骤2)获取的虾青素乳化液125g和步骤1)获得的提取液125g混匀,获得多糖混合液;
4):将用磷酸氢二钾与柠檬酸制成的缓冲液加入到步骤3)获得的多糖混合液中,PH调节至7;
5):将用黄原胶、槐豆胶制成的多糖胶液加入到步骤4)中调节PH后的多糖混合液中,匀质、悬浮化后,获得多糖悬浮液;
6):将步骤5)获得的多糖悬浮液瓶装、灭菌后获得产品。
实施例2:
1):称取黄芪60g、黄精60g、枸杞20g,加入7000g水,加热80℃,浸提时间为5小时后,离心除渣,获得提取液;
2):将虾青素油乳化获得虾青素乳化液120g;
3):将南瓜多糖100g、黄原胶50g、步骤2)获取的虾青素乳化液100g和步骤1)获得的提取液100g混匀,获得多糖混合液;
4):将用磷酸氢二钾与柠檬酸制成的缓冲液加入到步骤3)获得的多糖混合液中,PH调节至7;
5):将用黄原胶、槐豆胶制成的多糖胶液加入到步骤4)中调节PH后的多糖混合液中,匀质、悬浮化后,获得多糖悬浮液;
6):将步骤5)获得的多糖悬浮液瓶装、灭菌后获得产品。
实施例3:
1):称取黄芪1500g、黄精1500g、枸杞600g,加入36000g水,加热到100℃,浸提时间为1小时后,过滤除渣,获得提取液,备用;
2):将步骤1)获得的提取液浓缩、干燥,获得浓缩粉;
3):将虾青素油乳化获得虾青素乳化液6000g,将虾青素乳化液经低温真空干燥获得虾青素微囊粉;
4):将步骤2)获得的浓缩粉、步骤3)获得的虾青素微囊粉、南瓜多糖作为主要原料,加入食品添加剂、木糖醇后压片,获得片剂产品。
利用本发明制出的用于辅助治疗糖尿病的雨生红球藻虾青素产品,各种成分的量的要进行控制,以保证虾青素食用量为8-100mg/d,黄芪食用量为12-120g/d,黄精食用量为10-100g/d,枸杞食用量为10-200g/d,南瓜多糖食用量为5-100g/d。
Claims (6)
1.一种用于辅助治疗糖尿病的雨生红球藻虾青素产品的制备方法,其特征在于:包括以下步骤:
1):按2-5:2-5:1-2的比例称取黄芪、黄精、枸杞,加水,加热浸提,除渣,获得提取液;
2):将虾青素油乳化获得虾青素乳化液;
3):将南瓜多糖、黄原胶、步骤2)获取的虾青素乳化液和步骤1)获得的提取液按0.2-4:0.05-1:1-5:1-5的比例混匀,获得多糖混合液;
4):将缓冲液加入到步骤3)获得的多糖混合液中,PH调节至2-7.5;
5):将多糖胶液加入到步骤4)中调节PH值后的多糖混合液中,匀质、悬浮化后,获得多糖悬浮液;
6):将步骤5)获得的多糖悬浮液瓶装、灭菌后获得产品。
2.一种用于辅助治疗糖尿病的雨生红球藻虾青素产品的制备方法,其特征在于:包括以下步骤:
1):按2-5:2-5:1-2的比例称取黄芪、黄精、枸杞,加水,加热浸提,除渣,获得提取液;
2):将步骤1)获得的提取液浓缩、干燥,获得浓缩粉;
3):将虾青素油乳化获得虾青素乳化液,将虾青素乳化液经低温真空干燥获得虾青素微囊粉;
4):将步骤2)获得的浓缩粉、步骤3)获得的虾青素微囊粉、南瓜多糖作为主要原料,压片,获得片剂产品。
3.根据权利要求1或2所述的一种用于辅助治疗糖尿病的雨生红球藻虾青素产品的制备方法,其特征在于:所述步骤1)中的加水量为黄芪、黄精、枸杞总量的10-100倍,加热温度为60-100℃,浸提时间为1-8小时。
4.根据权利要求1或2所述的一种用于辅助治疗糖尿病的雨生红球藻虾青素产品的制备方法,其特征在于:所述步骤1)的除渣方法为过滤或离心。
5.根据权利要求1所述的一种用于辅助治疗糖尿病的雨生红球藻虾青素产品的制备方法,其特征在于:所述步骤3)的缓冲液为磷酸氢二钾与柠檬酸或磷酸氢二钾与酒石酸或磷酸氢二钾与苹果酸或磷酸氢二钾与乳酸或磷酸氢二钾与醋酸。
6.根据权利要求1所述的一种用于辅助治疗糖尿病的雨生红球藻虾青素产品的制备方法,其特征在于:所述步骤5)多糖胶液为黄原胶、槐豆胶、卡拉胶中的一种、两种或三种配置而成的胶液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610066177.0A CN105560838A (zh) | 2016-01-29 | 2016-01-29 | 一种用于辅助治疗糖尿病的雨生红球藻虾青素及其制造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610066177.0A CN105560838A (zh) | 2016-01-29 | 2016-01-29 | 一种用于辅助治疗糖尿病的雨生红球藻虾青素及其制造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105560838A true CN105560838A (zh) | 2016-05-11 |
Family
ID=55871850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610066177.0A Pending CN105560838A (zh) | 2016-01-29 | 2016-01-29 | 一种用于辅助治疗糖尿病的雨生红球藻虾青素及其制造方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105560838A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107048104A (zh) * | 2017-06-06 | 2017-08-18 | 荆楚理工学院 | 一种用于辅助治疗糖尿病的虾青素饮料 |
CN107279992A (zh) * | 2017-06-02 | 2017-10-24 | 杭州鑫伟低碳技术研发有限公司 | 一种用于保护视力改善记忆力的虾青素产品及其制备方法 |
CN107375368A (zh) * | 2017-06-02 | 2017-11-24 | 杭州鑫伟低碳技术研发有限公司 | 一种预防心血管疾病修复神经系统产品及其制备方法 |
CN107468677A (zh) * | 2017-07-05 | 2017-12-15 | 北京联合大学 | 雨生红球藻虾青素在制备预防和治疗糖尿病脑组织氧化损伤药物中的应用 |
CN110574871A (zh) * | 2018-06-11 | 2019-12-17 | 江苏帝尔生物科技有限公司 | 一种能够帮助控制血糖的营养代餐产品及其制备方法 |
US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101314621A (zh) * | 2008-07-23 | 2008-12-03 | 卢照凯 | 一种南瓜多糖及其制备方法 |
CN103494197A (zh) * | 2013-10-09 | 2014-01-08 | 吉林省现代中药工程研究中心有限公司 | 一种具有增强免疫力和辅助降血糖功能的保健食品及制备方法 |
CN103520199A (zh) * | 2013-11-05 | 2014-01-22 | 黑龙江八一农垦大学 | 枸杞多糖在治疗糖尿病药物中的应用 |
CN104856051A (zh) * | 2015-04-10 | 2015-08-26 | 杭州鑫伟低碳技术研发有限公司 | 一种利用雨生红球藻生产微囊虾青素粉的方法 |
CN104877882A (zh) * | 2015-06-30 | 2015-09-02 | 青岛浩大海洋保健食品有限公司 | 一种具有降血糖功效的虾青素复合配制酒 |
CN104997119A (zh) * | 2015-07-05 | 2015-10-28 | 青岛浩大海洋保健食品有限公司 | 一种具有降血糖功效的虾青素保健饮料 |
-
2016
- 2016-01-29 CN CN201610066177.0A patent/CN105560838A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101314621A (zh) * | 2008-07-23 | 2008-12-03 | 卢照凯 | 一种南瓜多糖及其制备方法 |
CN103494197A (zh) * | 2013-10-09 | 2014-01-08 | 吉林省现代中药工程研究中心有限公司 | 一种具有增强免疫力和辅助降血糖功能的保健食品及制备方法 |
CN103520199A (zh) * | 2013-11-05 | 2014-01-22 | 黑龙江八一农垦大学 | 枸杞多糖在治疗糖尿病药物中的应用 |
CN104856051A (zh) * | 2015-04-10 | 2015-08-26 | 杭州鑫伟低碳技术研发有限公司 | 一种利用雨生红球藻生产微囊虾青素粉的方法 |
CN104877882A (zh) * | 2015-06-30 | 2015-09-02 | 青岛浩大海洋保健食品有限公司 | 一种具有降血糖功效的虾青素复合配制酒 |
CN104997119A (zh) * | 2015-07-05 | 2015-10-28 | 青岛浩大海洋保健食品有限公司 | 一种具有降血糖功效的虾青素保健饮料 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107279992A (zh) * | 2017-06-02 | 2017-10-24 | 杭州鑫伟低碳技术研发有限公司 | 一种用于保护视力改善记忆力的虾青素产品及其制备方法 |
CN107375368A (zh) * | 2017-06-02 | 2017-11-24 | 杭州鑫伟低碳技术研发有限公司 | 一种预防心血管疾病修复神经系统产品及其制备方法 |
CN107048104A (zh) * | 2017-06-06 | 2017-08-18 | 荆楚理工学院 | 一种用于辅助治疗糖尿病的虾青素饮料 |
CN107468677A (zh) * | 2017-07-05 | 2017-12-15 | 北京联合大学 | 雨生红球藻虾青素在制备预防和治疗糖尿病脑组织氧化损伤药物中的应用 |
CN110574871A (zh) * | 2018-06-11 | 2019-12-17 | 江苏帝尔生物科技有限公司 | 一种能够帮助控制血糖的营养代餐产品及其制备方法 |
US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105560838A (zh) | 一种用于辅助治疗糖尿病的雨生红球藻虾青素及其制造方法 | |
CN101756244A (zh) | 一种适用于糖尿病人群的功能性食品 | |
CN102138655B (zh) | 桂圆补血膏配方及其制作方法 | |
CN105148077A (zh) | 一种具有降血糖功效的养生粥 | |
CN108185441A (zh) | 一种治疗糖尿病的配方食品及其制备方法 | |
CN106924374A (zh) | 一种组合物及其制备方法与在制备降血糖和/或降血脂的产品中的应用 | |
CN104083640B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN105395706A (zh) | 用于糖尿病的保健品 | |
CN103518878B (zh) | 一种润肠健胃蜂蜜醋饮料以及制备方法 | |
CN104189418A (zh) | 一种降血糖血压的洋葱制剂及其制备方法 | |
CN113057315A (zh) | 一种辅助降血糖的保健食品及其制备方法 | |
CN105994867A (zh) | 一种具有提高免疫力的巧克力及其制备方法 | |
CN103238713B (zh) | 一种养益心脏的食品养生茶冲剂 | |
CN102626162A (zh) | 一种养益心脏的营养食品养心茶冲剂 | |
CN102389540A (zh) | 健脾胃葡萄糖酸钙口服液 | |
CN104857289A (zh) | 一种降血糖血压的人参制剂及其制备方法 | |
CN105077467A (zh) | 一种具有降血糖功效的鲍参保健饮料 | |
CN107737280A (zh) | 用于治疗糖尿病的中药组合物及其制备方法和应用 | |
CN114042132A (zh) | 锦灯笼宿萼醇提物在制备糖尿病药物中的应用 | |
CN104920723A (zh) | 一种配合治疗消渴症的茶饮料及其制作方法 | |
CN105343601A (zh) | 一种抗衰老羊胎素口服液及制备方法 | |
CN104106713A (zh) | 香橙口味的营养型荞麦果茶饮料及其制备方法 | |
CN104000180A (zh) | 一种辅助降血糖的人参组合物、制备方法及其用途 | |
CN107518404A (zh) | 一种新鲜石斛保健胶粒及制备方法 | |
CN104382165A (zh) | 一种降糖翻白草大豆蛋白肽饮料及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |